MX2020005864A - Inhibidores de dopamina-b-hidroxilasa. - Google Patents
Inhibidores de dopamina-b-hidroxilasa.Info
- Publication number
- MX2020005864A MX2020005864A MX2020005864A MX2020005864A MX2020005864A MX 2020005864 A MX2020005864 A MX 2020005864A MX 2020005864 A MX2020005864 A MX 2020005864A MX 2020005864 A MX2020005864 A MX 2020005864A MX 2020005864 A MX2020005864 A MX 2020005864A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- solvates
- dopamine
- salts
- hydroxylase inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a: (a) compuestos de la fórmula Ia (con R1, R4 a R6, n y A como se definieron con anterioridad) y sus sales o solvatos farmacéuticamente aceptables que son de utilidad como inhibidores de dopamina-ß-hidroxilasa; (b) composiciones farmacéuticas que comprenden tales compuestos, sales o solvatos; (c) el uso de tales compuestos, sales o solvatos en terapia; (d) métodos terapéuticos de tratamiento que usan tales compuestos, sales o solvatos; y (e) procesos e intermediarios de utilidad para la síntesis de tales compuestos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1720189.8A GB201720189D0 (en) | 2017-12-04 | 2017-12-04 | Dopamine-B-hydroxylase inhibitors |
GBGB1804439.6A GB201804439D0 (en) | 2018-03-20 | 2018-03-20 | Dopamin-b-hydroxylase inhibitors |
PCT/PT2018/050043 WO2019112457A1 (en) | 2017-12-04 | 2018-11-30 | Dopamine-β-hydroxylase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020005864A true MX2020005864A (es) | 2020-09-09 |
Family
ID=65012066
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020005864A MX2020005864A (es) | 2017-12-04 | 2018-11-30 | Inhibidores de dopamina-b-hidroxilasa. |
Country Status (16)
Country | Link |
---|---|
US (2) | US11434242B2 (es) |
EP (1) | EP3720856A1 (es) |
JP (1) | JP7167155B2 (es) |
KR (1) | KR20200096584A (es) |
CN (1) | CN111479812A (es) |
AU (1) | AU2018379646A1 (es) |
BR (1) | BR112020010216A2 (es) |
CA (1) | CA3082337A1 (es) |
CL (1) | CL2020001461A1 (es) |
IL (1) | IL274550B2 (es) |
MX (1) | MX2020005864A (es) |
PH (1) | PH12020500542A1 (es) |
RU (1) | RU2020121820A (es) |
SG (1) | SG11202004231YA (es) |
TW (1) | TW201925193A (es) |
WO (1) | WO2019112457A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019112457A1 (en) | 2017-12-04 | 2019-06-13 | BIAL - PORTELA & Cª, S.A. | Dopamine-β-hydroxylase inhibitors |
GB201908044D0 (en) | 2019-06-05 | 2019-07-17 | Bial Portela & Ca Sa | Dopamine-B-Hydroxylase inhibitors |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3635982A (en) | 1969-04-08 | 1972-01-18 | American Home Prod | Amino-substituted-quinoxalinyloxazolidines and -oxazines |
FR2449689A1 (fr) | 1979-02-20 | 1980-09-19 | Logeais Labor Jacques | Nouveaux derives condenses de pyrrolidine ou de piperidine, leur procede de preparation et leurs applications en therapeutique |
US4628059A (en) | 1985-10-31 | 1986-12-09 | Smithklein Beckman Corporation | Dopamine-β-hydroxylase inhibitors |
AU687192B2 (en) | 1994-04-26 | 1998-02-19 | Syntex (U.S.A.) Inc. | Benzocycloalkylazolethione derivatives |
US6482982B1 (en) | 2001-03-09 | 2002-11-19 | University Of Sciences Of Philadelphia | Halogenated antituberculosis agents |
IL143379A (en) | 2001-05-24 | 2013-11-28 | Yissum Res Dev Co | Oligonucleotide against human ache isoform r and its uses |
US7125904B2 (en) | 2002-10-11 | 2006-10-24 | Portela & C.A., S.A. | Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation |
WO2008085008A1 (en) | 2007-01-11 | 2008-07-17 | Mogam Biotechnology Research Institute | T-cell inhibiting compounds and their use for the treatment of t-cell-mediated diseases |
GB0708818D0 (en) | 2007-05-08 | 2007-06-13 | Portela & Ca Sa | Compounds |
EP2182952A4 (en) | 2007-07-23 | 2010-09-08 | Synosia Therapeutics | TREATMENT OF POST-TRAUMATIC STRESS DISORDER |
US8110578B2 (en) * | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
WO2014127350A1 (en) | 2013-02-18 | 2014-08-21 | The Scripps Research Institute | Modulators of vasopressin receptors with therapeutic potential |
JOP20190050A1 (ar) | 2016-09-23 | 2019-03-20 | Bial Portela & C? S A | مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي |
WO2019112457A1 (en) | 2017-12-04 | 2019-06-13 | BIAL - PORTELA & Cª, S.A. | Dopamine-β-hydroxylase inhibitors |
-
2018
- 2018-11-30 WO PCT/PT2018/050043 patent/WO2019112457A1/en unknown
- 2018-11-30 CN CN201880080871.5A patent/CN111479812A/zh active Pending
- 2018-11-30 MX MX2020005864A patent/MX2020005864A/es unknown
- 2018-11-30 SG SG11202004231YA patent/SG11202004231YA/en unknown
- 2018-11-30 TW TW107143059A patent/TW201925193A/zh unknown
- 2018-11-30 KR KR1020207019157A patent/KR20200096584A/ko not_active Application Discontinuation
- 2018-11-30 RU RU2020121820A patent/RU2020121820A/ru unknown
- 2018-11-30 JP JP2020530502A patent/JP7167155B2/ja active Active
- 2018-11-30 US US16/769,045 patent/US11434242B2/en active Active
- 2018-11-30 AU AU2018379646A patent/AU2018379646A1/en not_active Abandoned
- 2018-11-30 BR BR112020010216-4A patent/BR112020010216A2/pt unknown
- 2018-11-30 CA CA3082337A patent/CA3082337A1/en active Pending
- 2018-11-30 EP EP18833340.5A patent/EP3720856A1/en not_active Withdrawn
-
2020
- 2020-05-10 IL IL274550A patent/IL274550B2/en unknown
- 2020-06-01 CL CL2020001461A patent/CL2020001461A1/es unknown
- 2020-06-02 PH PH12020500542A patent/PH12020500542A1/en unknown
-
2022
- 2022-09-01 US US17/901,007 patent/US20230138795A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3720856A1 (en) | 2020-10-14 |
AU2018379646A1 (en) | 2020-06-11 |
US20210171528A1 (en) | 2021-06-10 |
CA3082337A1 (en) | 2019-06-13 |
KR20200096584A (ko) | 2020-08-12 |
CL2020001461A1 (es) | 2020-10-16 |
IL274550A (en) | 2020-06-30 |
PH12020500542A1 (en) | 2021-01-25 |
CN111479812A (zh) | 2020-07-31 |
JP7167155B2 (ja) | 2022-11-08 |
WO2019112457A1 (en) | 2019-06-13 |
TW201925193A (zh) | 2019-07-01 |
SG11202004231YA (en) | 2020-06-29 |
US11434242B2 (en) | 2022-09-06 |
RU2020121820A (ru) | 2022-01-10 |
IL274550B2 (en) | 2023-06-01 |
JP2021505568A (ja) | 2021-02-18 |
US20230138795A1 (en) | 2023-05-04 |
BR112020010216A2 (pt) | 2020-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123810T1 (el) | Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα | |
PH12019500568A1 (en) | Dopamine-b-hydroxylase inhibitors | |
PH12020551717A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
PH12018500065A1 (en) | Oxysterols and methods of use thereof | |
PH12020550503A1 (en) | Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors | |
EP3970712A3 (en) | Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof | |
MX2019014292A (es) | Anillos 5-5 fusionados como inhibidores c5a. | |
MX2018000419A (es) | Derivados de amida sustituida que tienen actividad multimodal contra el dolor. | |
MX2019006721A (es) | Tratamiento para la colangitis biliar primaria. | |
MX2023014492A (es) | Compuestos utiles en la terapia para el vih. | |
MX2020010942A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
MX2015014083A (es) | Inhibidores de enzima de escision de proteina precursora beta-amiloide (app) en el sitio beta 1 (bace1). | |
MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
CY1124907T1 (el) | Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα | |
TR201819805T4 (tr) | Flavaglin türevleri̇. | |
MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
PH12020500542A1 (en) | Dopamine-b-hydroxylase inhibitors | |
MX2017013101A (es) | Piridopirimidinonas y utilizacion de las mismas como moduladores de receptores de n-metil-d-aspartato (nmda). | |
PH12021550143A1 (en) | Pyridopyrimidines as histamine h4-receptor inhibitors | |
PH12017501668A1 (en) | Bace1 inhibitors | |
PH12016502480A1 (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | |
MX2015015290A (es) | Compuestos furanona como inhibidores de quinasa. | |
MX2021014941A (es) | Inhibidores de dopamina-b-hidroxilasa. | |
MX2017013103A (es) | Metodos para el tratamiento de trastornos cardiovasculares. | |
MX2016016061A (es) | 2,2,2-trifluoroetil-tiadiazinas. |